Early Chk1 Phosphorylation Is Driven by Temozolomide-Induced, DNA Double Strand Break- and Mismatch Repair-Independent DNA Damage

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Ito, Motokazu ^a,b   Ohba, Shigeo ^a,b   Gaensler, Karin ^b   Ronen, Sabrina M ^a,b   Mukherjee, Joydeep ^a,b   Pieper, Russell O ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN TYROSINE PHOSPHATASE; REACTIVE OXYGEN METABOLITE; TEMOZOLOMIDE;

ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; DNA ADDUCT; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLIOMA CELL; HUMAN; HUMAN CELL; MISMATCH REPAIR;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DACARBAZINE; DNA BREAKS, DOUBLE-STRANDED; DNA BREAKS, SINGLE-STRANDED; DNA METHYLATION; DNA MISMATCH REPAIR; ENZYME ACTIVATION; HUMANS; PHOSPHORYLATION; PROTEIN KINASES; TIME FACTORS;

EID: 84877120704     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062351     Document Type: Article

References (44)

1. Osoba D, Brada M, Yung YKA, Prados MP (2000) Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. 18, 1481-1491.
2. Johnson DR, O'Neill BP (2012) Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 107, 359-364.
3. Neidle S, Thurston DE (2005) Chemical approaches to the discovery and development of cancer therapies. Nature Rev. Cancer 5, 285-296.
4. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 23, 35-61.
5. Boysen G, Pachkowski BF, Nakamura J, Swenberg JA (2009) The formation and biological significance of N7-guanine adducts. Mut. Res. 678, 76-94.
6. Lindahl T (1993) Instability and decay of the primary structure of DNA. Nature 362, 709-715.
7. Dianov GL, Sleeth KM, Dianov II, Allinson SL (2003) Repair of abasic sites in DNA. Mutation Res. 203, 157-163.
8. Abbotts R, Madhusudan S (2010) Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev. 36, 425-435.
9. Riazuddin S, Lindahl T (1978) Properties of 3-methyladenine-DNA glycosylase from Escherichia coli. Biochemistry 17, 2110-2118.
10. Sobol RW, Horton JK, Kuhn R, Gu H, Singhal R, et al. (1996) Requirement of mammalian DNA polymerase-beta in base-excision repair. Nature 379, 183-186.
11. Wyatt MD, Allan JM, Lau AY, Ellenberger TE, Samson LD (1999) 3- methyladenine DNA glycosylases: structure, function, and biological importance. BioEssays 21, 668-676.
12. Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, et al. (2005) Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res. 11, 3402-309.
13. Margison GP, Koref MF, Povey A (2002) Mechanisms of carcinogenicity/ chemotherapy by O6-methylguanine. Mutagenesis 17, 483-487.
14. Karran P, Marinus MG (1982) Mismatch correction at O6-methylguanine residues in E. coli DNA. Nature 296, 868-869.
15. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, et al. (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharm. 54, 334-341.
16. Hirose Y, Berger MS, Pieper RO (2001) p53 Effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 61, 1957-1963.
17. Quiros S, Roos WP, Kaina B (2010) Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle 9, 168-178.
18. Hirose Y, Berger MS, Pieper RO (2001) Abrogation of the Chk1-mediated G2 checkpoint pathway potentiates temozolomide-induced toxicity in a p53- independent manner in human glioblastoma cells. Cancer Res. 61, 5843-5849.
19. Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, et al. (2003) The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNAmethylating agents. Mol. Cell. Biol. 23, 8306-8315.
20. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO (2005) Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide -induced mitotic catastrophe and cellular senescence. Cancer Res. 65, 4587-4596.
21. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, et al. (2007) Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26, 186-197.
22. Pegg AE, Wiest L, Foote RS, Mitra S, Perry W (1983) Purification and properties of O6-methylguanine-DNA transmethylase from rat liver. J. Biol. Chem. 258, 2327-2333.
23. Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BKA, et al. (1997) Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft Cancer Res. 57, 2933-2936.
24. Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, et al. (2010) In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18, 244-257.
25. Dai Y, Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. 16, 376-383.
26. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, et al. (2004) DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol. Pharm. 66, 478-491.
27. Adamson AW, Kim WJ, Shangary S, Baskaran R, Brown KD (2002) ATM is activated in response to N-methyl-N'-nitro-N-nitrosoguanidine-induced DNA alkylation. J. Biol. Chem. 277, 38222-38229.
28. Stojic L, Mojas N, Cejka P, Di Pietro M, Ferrari S, et al. (2004) Mismatch repairdependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase Genes and Dev. 18: 1331-1344.
29. Wang XZ, Weaver DT (2011) The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am. J. Cancer Res. 1, 301-327.
30. Stojic L, Cejka P, Jiricny J (2005) High doses of SN1 type methylating agents activate DNA damage signaling cascades that are largely independent of mismatch repair. Cell Cycle 4, 473-477.
31. Westphal M, Hansel M, Hamel W, Kunzmann R, Holzel F (1994) Karyotype analyses of 20 human glioma cell lines. Acta Neurochir (Wien) 126, 17-26.
32. Xu-Welliver M, Kanugugla S, Pegg AE (1998) Isolation of human O6- alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine. Cancer Res. 58, 1936-1945.
33. Mirzoeva OK, Pieper RO (2006) The Mre11/Rad50/Nbs1 (MRN) complex interacts with the mismatch repair system and contributes to temozolomideinduced G2 arrest and cytotoxicity. Mol. Cancer Ther. 5, 2757-2766.
34. Chen CC, Kahle KT, Ng K, Nitta M, D'Andrea A (2009) Of Escherichia coli and man: understanding glioma resistance to temozolomide therapy. In: Van Meir, EG, editor. CNS Cancer, Cancer Drug Discovery and Development. New York: Human Press. 680-703.
35. Zhang W, Wang Z, Shu F, Jin Y-H, Liu H, Wang Q, Yang Y (2010) Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J. Biol. Chem. 285, 40461-40471.
36. Huang XJ, Li CT, Zhang WP, Lu YB, Fang SH, Wei EQ (2008) Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells. Pharmacology 82, 1-9.
37. Singer B, Brent TP (1981) Human lymphoblasts contain DNA glycosylase activity excising N-3 and N-7 methyl and ethyl purines but not O6-alkylguanines or 1-alkyladenines. Proc. Natl. Acad. Sci. 78, 856-860.
38. Naidu MD, Mason JM, Pica RV, Fung H, Peña LA (2010) Radiation resistance in glioma cells determined by DNA damage repair activity of Ape1/Ref-1. J Radiat Res (Tokyo) 51, 393-404.
39. Pegg AE (1990) Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50, 6119-6129.
40. Garvik B, Carson M, Hartwell L (1995) Single-stranded DNA arising at telomeres in cdc13 mutants may constitute a specific signal for the RAD9 checkpoint. Mol. Cell. Biol. 15, 6128-6138.
41. Zhao H, Piwnica-Worms H (2001) ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol. 21, 4129-4139.
42. Adamson AW, Beardsley DI, Kim W-J, Gao Y, Baskaran R, Brown KD (2005) Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2 Mol. Biol. Cell. 16, 1513-1526.
43. Au KG, Welsh K, Modrich P (1992) Initiation of methyl-directed mismatch repair. J. Biol. Chem. 267, 12142-12148.
44. Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, et al. (2011) Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J Magn Reson Imaging. 33, 1284-1290.